爱美客(300896) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥389,636,635.96, representing a 75.09% increase year-over-year, while total revenue for the year-to-date was ¥1,023,097,508.89, up 120.29% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2021 was ¥283,441,129.32, an increase of 98.01% year-over-year, with a year-to-date net profit of ¥708,913,425.63, reflecting a 144.09% increase[3]. - The total revenue for the third quarter of 2021 reached 835,923,433.92, representing a 150.57% increase compared to the same period last year[8]. - Net profit for the third quarter was 708,448,215.30, reflecting a 147.98% increase year-over-year[8]. - The total profit before tax was 831,172,090.87, up 149.14% from the previous year[8]. Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥671,892,622.78, which is a 159.67% increase compared to the same period last year[4]. - The company reported a 119.08% increase in cash received from sales, totaling 1,027,185,645.09 for the first nine months of 2021[9]. - The company received other operating cash inflows of 44,086,479.22, a significant increase of 1105.83% year-over-year[8]. - The net cash flow from operating activities indicates a robust operational performance, supporting future growth initiatives and potential market expansion strategies[24]. - The cash inflow from operating activities was CNY 1,076,003,257.05, significantly higher than CNY 479,027,069.56 in the previous year[25]. Assets and Liabilities - Total assets as of the end of Q3 2021 amounted to ¥4,983,968,303.65, a 7.58% increase from the end of the previous year[4]. - The company's equity attributable to shareholders was ¥4,784,319,865.23, which is a 5.53% increase from the end of the previous year[4]. - The total liabilities and equity as of Q3 2021 amounted to CNY 4,983,968,303.65, up from CNY 4,632,668,833.13 in the previous year[20]. - The total liabilities included accounts payable of CNY 4,559,011.00 and contract liabilities of CNY 17,216,095.95[30]. - Total liabilities amounted to CNY 101,444,659.98, with current liabilities at CNY 89,205,738.66[31]. Expenses - Research and development expenses increased by 86.50% to 61,658,347.65, indicating a significant investment in innovation[8]. - Sales expenses surged by 138.83% to 100,351,573.40, primarily due to increased personnel costs[8]. - The company experienced a significant increase in sales expenses, which rose to CNY 100,351,573.40 from CNY 42,017,237.56, reflecting increased marketing efforts[21]. - The company experienced a decrease in cash flow due to increased operational expenses, with cash paid to employees rising to CNY 129,763,129.72 from CNY 85,777,926.49[25]. Equity and Shares - The company reported a total of 166,981,313 shares with 54,729,828 shares released from lock-up during the reporting period[13]. - The total equity attributable to shareholders of the parent company increased to CNY 4,784,319,865.23 from CNY 4,533,816,111.30 year-over-year[20]. - The company reported an unallocated profit of CNY 808,888,734.06, contributing to overall equity growth[31]. Product Development and Market Strategy - The company launched a new product, "滞白天使," which has received positive feedback and contributed to revenue during the reporting period[14][16]. - The company has established a system for doctors to apply for injection licenses, enhancing the integration of quality medical services with its products[14]. Accounting and Reporting - The company has adopted new leasing standards effective from January 1, 2021, impacting financial statements[32]. - The third quarter report was not audited, indicating preliminary financial data[32].